| 1 |
International evidence-based recommendations for point-of-care lung ultrasound
Giovanni Volpicelli et al. · Intensive Care Medicine
Open access |
5 Mar 2012 |
2,919 |
| 2 |
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor R. Mirza et al. · New England Journal of Medicine
Open access |
8 Oct 2016 |
2,495 |
| 3 |
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S Abramson et al. · The Lancet
|
Sep 2020 |
2,422 |
| 4 |
Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer
Andrew N.J. Tutt et al. · New England Journal of Medicine
Open access |
3 Jun 2021 |
1,744 |
| 5 |
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia et al. · New England Journal of Medicine
Open access |
21 Apr 2021 |
1,671 |
| 6 |
Task Group 142 report: Quality assurance of medical acceleratorsa)
Eric Klein, Joseph Hanley, John E. Bayouth et al. · Medical Physics
Open access |
17 Aug 2009 |
1,632 |
| 7 |
International evidence-based recommendations on ultrasound-guided vascular access
Massimo Lamperti, Andrew R Bodenham, Mauro Pittiruti et al. · Intensive Care Medicine
Open access |
21 May 2012 |
836 |
| 8 |
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Manali Kamdar et al. · The Lancet
Open access |
Jun 2022 |
799 |
| 9 |
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Paula Rodríguez‐Otero et al. · New England Journal of Medicine
Open access |
10 Feb 2023 |
768 |
| 10 |
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia
Stefan Octavian Ciurea et al. · Blood
Open access |
Jul 2015 |
664 |
| 11 |
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Matthew Steven Davids et al. · New England Journal of Medicine
Open access |
13 Jul 2016 |
604 |
| 12 |
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis
Javier Bolaños‐Meade et al. · New England Journal of Medicine
Open access |
21 Jun 2023 |
599 |
| 13 |
Age Limit of Pediatrics
Amy Peykoff Hardin, Jesse M. Hackell, Geoffrey R. Simon et al. · PEDIATRICS
|
21 Aug 2017 |
581 |
| 14 |
Electrophysiologic Testing to Identify Patients with Coronary Artery Disease Who Are at Risk for Sudden Death
Alfred E. Buxton, Kerry L. Lee, Lorenzo A. DiCarlo et al. · New England Journal of Medicine
Open access |
29 Jun 2000 |
566 |
| 15 |
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Nancy U. Lin et al. · Journal of Clinical Oncology
Open access |
29 May 2020 |
558 |
| 16 |
T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation
Asad Bashey, Xu Zhang, Connie A. Sizemore et al. · Journal of Clinical Oncology
|
19 Feb 2013 |
503 |
| 17 |
Pulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter Thrombolysis (PERFECT)
William T. Kuo, Arjun Banerjee, Paul S. Kim et al. · CHEST Journal
|
9 Apr 2015 |
476 |
| 18 |
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
Makoto Nishio, Fabrice Barlési, Howard West et al. · Journal of Thoracic Oncology
Open access |
16 Dec 2020 |
473 |
| 19 |
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
Christopher Simon Hourigan et al. · Journal of Clinical Oncology
Open access |
20 Dec 2019 |
456 |
| 20 |
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
Paolo Fabrizio Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio et al. · The Lancet Oncology
|
11 May 2021 |
440 |
| 21 |
Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease
Partow Kebriaei, Luis M Isola, Erkut Bahceci et al. · Transplantation and Cellular Therapy
Open access |
17 Jun 2009 |
436 |
| 22 |
Noninvasive Measurement of Total Serum Bilirubin in a Multiracial Predischarge Newborn Population to Assess the Risk of Severe Hyperbilirubinemia
Vinod K. Bhutani, Glenn R. Gourley, Saul M. Adler et al. · PEDIATRICS
|
Aug 2000 |
421 |
| 23 |
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
Jeremy S. Abramson, Scott R. Solomon, Jon E. Arnason et al. · Blood
Open access |
21 Dec 2022 |
395 |
| 24 |
Management of Acute Myocardial Infarction During the COVID-19 Pandemic
Ehtisham Mahmud, Harold L. Dauerman, Frederick G.P. Welt et al. · Journal of the American College of Cardiology
Open access |
21 Apr 2020 |
395 |
| 25 |
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
Asad Bashey, Bridget Medina, Sue Corringham et al. · Blood
Open access |
31 Oct 2008 |
367 |
| 26 |
Association of Red Blood Cell Transfusion, Anemia, and Necrotizing Enterocolitis in Very Low-Birth-Weight Infants
Ravi M. Patel, Andrea Knežević, Neeta V. Shenvi et al. · JAMA
Open access |
Mar 2016 |
358 |
| 27 |
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
Jeffrey E. Lancet, Jörge E. Cortes, Donna E. Hogge et al. · Blood
Open access |
Apr 2014 |
341 |
| 28 |
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
Aditya Bardia et al. · Annals of Oncology
Open access |
8 Jun 2021 |
322 |
| 29 |
Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of a Prospective Phase II Trial
Scott R. Solomon, Connie A. Sizemore, Melissa Sanacore et al. · Transplantation and Cellular Therapy
Open access |
31 Jul 2012 |
304 |
| 30 |
South Asians and Cardiovascular Risk
Milan Gupta, Narendra Singh, Subodh Verma · Circulation
|
26 Jun 2006 |
294 |
| 31 |
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control g
Javier Bolaños‐Meade et al. · The Lancet Haematology
Open access |
26 Feb 2019 |
288 |
| 32 |
Ten things to know about ten cardiovascular disease risk factors
Harold Edward Bays, Pam R. Taub, Elizabeth Epstein et al. · American Journal of Preventive Cardiology
Open access |
23 Jan 2021 |
275 |
| 33 |
The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation
Stefan Octavian Ciurea et al. · Bone Marrow Transplantation
Open access |
9 Jan 2018 |
259 |
| 34 |
PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD
Bradley M. Haverkos et al. · Blood
Open access |
3 May 2017 |
249 |
| 35 |
An unseen danger: Frequency of posterior vessel wall penetration by needles during attempts to place internal jugular vein central catheters using ultrasound guidance*
Michael Blaivas, Srikar Adhikari · Critical Care Medicine
|
Aug 2009 |
244 |
| 36 |
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
Alison R. Sehgal et al. · The Lancet Oncology
|
12 Jul 2022 |
242 |
| 37 |
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
Jeffrey E. Lancet, Geoffrey L. Uy, Laura F. Newell et al. · The Lancet Haematology
|
22 Jun 2021 |
228 |
| 38 |
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3
Mark J. Levis et al. · Journal of Clinical Oncology
Open access209 authors |
12 Mar 2024 |
221 |
| 39 |
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial
Ephraim Joseph Fuchs, Paul V. O’Donnell, Mary Eapen et al. · Blood
Open access |
Sep 2020 |
217 |
| 40 |
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases
Nancy U. Lin et al. · JAMA Oncology
Open access |
Dec 2022 |
211 |
| 41 |
Needle tip visualization during ultrasound-guided vascular access: short-axis vs long-axis approach
Michael Benjamin Stone, Cynthia H. Moon, Darrell Sutijono et al. · The American Journal of Emergency Medicine
|
29 Jan 2010 |
210 |
| 42 |
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial
Kevin M. Kalinsky et al. · Journal of Clinical Oncology
|
19 May 2023 |
209 |
| 43 |
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study
Tanya Siddiqi et al. · The Lancet
Open access |
6 Jun 2023 |
208 |
| 44 |
The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy
John R Harsh, Roza Hayduk, Russell P. Rosenberg et al. · Current Medical Research and Opinion
|
20 Mar 2006 |
199 |
| 45 |
Potential Risks of Pharmacy Compounding
Jennifer Gudeman, Michael J. Jozwiakowski, John L. Chollet et al. · Drugs in R&D
Open access |
Mar 2013 |
198 |
| 46 |
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
Josep M. del Campo et al. · Journal of Clinical Oncology
Open access |
7 Jun 2019 |
196 |
| 47 |
The accuracy of clinical neurosensory testing for nerve injury diagnosis
John Randall Zuniga, Roger Albert Meyer, John M. Gregg et al. · Journal of Oral and Maxillofacial Surgery
|
1998 |
191 |
| 48 |
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001
Jeremy S. Abramson, Maria Lia Palomba, Leo I. Gordon et al. · Blood
Open access |
27 Oct 2023 |
189 |
| 49 |
Blood Transfusion and Breast Milk Transmission of Cytomegalovirus in Very Low-Birth-Weight Infants
Cassandra D. Josephson, Angela M. Caliendo, Kirk A. Easley et al. · Archives of Pediatrics and Adolescent Medicine
Open access |
22 Sep 2014 |
188 |
| 50 |
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis
Scott Ryan Goldsmith et al. · Blood
Open access |
3 Mar 2021 |
185 |